The German medtech company analyses biomarker constellations with advanced nuclear magnetic resonance and artificial intelligence to improve diagnostics.
The company develops multi-biomarker diagnostic tests to improve organ function assessment for patients with kidney, heart and liver disease, as well as cancer and multiple sclerosis.
Another €20 million for marketing the product is provided by existing Numares investors.
The European Investment Bank (EIB) has signed a quasi-equity financing agreement of up to €20 million with Numares Health AG. The Regensburg-based company has developed a fully automated in-vitro diagnostics (IVD) platform, the AXINON® system. It improves diagnostic quality for chronic diseases of the kidney, heart and liver, as well as cancer and multiple sclerosis.
AXINON® combines nuclear magnetic resonance (NMR) and artificial intelligence to collect metabolomics data from liquid biopsy samples like urine and blood. Instead of focusing on single markers, Numares uses nuclear magnetic resonance to evaluate groups of metabolites (known as metabolite constellations) that are analysed using machine learning.
This chemical-free technology is already used by several major laboratories in the United States. The laboratories and Numares share the profits of the faster and more accurate results delivered by the technology. For example, with Numares technology, rejections reactions following kidney transplantations can be detected sooner and more accurately.
Numares will use the EIB financing (a €20 million quasi-equity facility) for further research and development. Existing investors will contribute to an additional €20 million for investments in the mass marketing of the proprietary technology products in the European Union and the United States.
The loan is part of the European Guarantee Fund’s venture debt financing. This product has been designed in response to the consequences of the coronavirus pandemic, which have further deteriorated commercial banks’ willingness to provide financing for risk investment into innovative technology companies like Numares. The benefit of this is a clear enhancement to the EIB’s risk-taking capacity, with a view to addressing sub-optimal investment situations arising from the pandemic.
“We are proud to support this innovative health-company,” said EIB-Vice-President Ambroise Fayolle. “We see the promise of improved multi-marker diagnostics that could help patients where single marker diagnostics have failed or been inadequate.”
Numares CEO Winton Gibbons said: “The Numares approach holds the potential to answer medical questions where current diagnostics have been inadequate. The use of artificial intelligence and highly standardised NMR data will result in a variety of algorithms to diagnose and manage a number of diseases. With the EIB venture debt financing, we will bring this novel, revolutionary technology to the patients who need better diagnostic tools.”
The EIB’s activities focus on the following priority areas: climate and environment, development, innovation and skills, small and medium-sized businesses, infrastructure and cohesion. The EIB works closely with other EU institutions to foster European integration, promote the development of the European Union and support EU policies in over 140 countries around the world.
The European Guarantee Fund (EGF) was created by 22 EU Member States in response to the coronavirus pandemic. With state guarantees of about €25 billion, the EIB can mobilise up to €200 billion to support small and medium-sized companies suffering from the economic fall out of the pandemic.
Numares Health AG is a healthcare company using artificial intelligence-enabled technology to develop novel diagnostic tests to help physicians improve care for their patients with chronic diseases, including kidney, cardiovascular, liver and neurological conditions.
Numares develops advanced tests to aid in diagnosis and measurement of disease progression by applying machine learning to metabolomics and other biomarkers. The company developed the AXINON® system that uses next-generation nuclear magnetic resonance spectroscopy to evaluate metabolic constellations and a proprietary Magnetic Group Signaling (MGS®) technology that enables the spectroscopy.
Numares AG is a medtech company based in Regensburg (Germany) with subsidiaries in Boston and Singapore. Founded in 2004 as a spin-off of Regensburg University, the Company employs 60 FTEs. It focuses on the development of Axinon, a modular software-based system for diagnostics based on nuclear magnetic resonance (NMR) metabolomics with multiple applications. The project will consist in completing the ongoing clinical studies in conjunction with relevant cost items providing Numares with suffici
The European Investment Bank (EIB) today launched the sixth edition of its Climate Survey. These are some of the most striking results of this annual survey conducted in August and September 2023. Running since 2018, the EIB Climate Survey offers insights into the climate change-related views of people in major economies around the world, with more than 30 000 respondents in the European Union, the United States, China, India, Japan, the United Kingdom, UAE, Canada and South Korea. The EIB is the lending arm of the European Union and the world’s largest multilateral lender for climate action projects.
Contributing to the electrification, efficiency and safety of the transport sector through investments in research, development and innovation are the key objectives of the financing granted by the EIB to Iveco Group (EXM: IVG), a global leader in the automotive sector, active in the commercial and special vehicles, powertrain and related financial services segments.
ABB and the European Investment Bank (EIB), the lending arm of the European Union, have signed a €500 million financing agreement to support ABB’s research and development in its Electrification business area.